Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.

Biochemical pharmacology - 1 Jul 2023

He Chunxiao, Peng Zhiyong, Zhang Dengyang, Guo Yao, Liang Tianqi, Zhao Yuming, Yu Liuting, Zhang Qi, Chang Zhiguang, Xiao Yan, Li Na, Xue Hongman, Wu Shunjie, Zhao Zhizhuang Joe, Zhang Changhua, Chen Yun

Abstract excerpt

Leukemogenic SHP2 mutations occur in 35% of patients with juvenile myelomonocytic leukemia (JMML), a hematopoietic malignancy with poor response to cytotoxic chemotherapy. Novel therapeutic strategies are urgently needed for patients with JMML. Previously, we established a novel cell model of JMML with HCD-57, a murine erythroleukemia cell line that depends on EPO for survival. SHP2-D61Y or -E76K drove the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Leukemia, Myelomonocytic, Juvenile

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Signal Transduction

Share to Sunitinib

Source

Identifiers

PMID: 37187274
DOI: 10.1016/j.bcp.2023.115588

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.PMID 37187274Read ↗

Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.Semantic proximity Read ↗

Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?Semantic proximity Read ↗

Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemiaSemantic proximity Read ↗

Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.Semantic proximity Read ↗

SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.Semantic proximity Read ↗

R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.Semantic proximity Read ↗

Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.Semantic proximity Read ↗

Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.Semantic proximity Read ↗

Oncogenic PTPN11/SHP2 drives immune escape in juvenile myelomonocytic leukemia (JMML) through activation of ectonucleotidase/adenosine signalingSemantic proximity Read ↗

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology GroupSemantic proximity Read ↗

The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo.Semantic proximity Read ↗

Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.